StockNow
Calendar
Log in
U.S. Markets

Merk (MRK) reports Phase 2b/3 results for remigromig in diabetic macular edema

StockNow breaking-news AI analysis

On September 24, 2026, Merk reported Phase 2b/3 trial results for remigromig in diabetic macular edema, with detailed study data not yet disclosed.

1 stocks
MRKMerck & Co., Inc.$148.48Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Oracle (ORCL) sends force majeure notice over New Mexico data centre; trying to put off payments on project if it's delayed

ORCLGeopolitics

Chinese Foreign Minister says the Strait of Hormuz conflict must be resolved through dialogue and calls on all parties to seek a peaceful solution, Al Arabiya reports

Geopolitics

An Israeli source says "we do not see a real chance of reaching an agreement between the United States and Iran", Al Hadath reports